These are general statistics based on large groups of patients. The researchers looked at different treatment combinations for people with anal cancer. The results below are for progression free survival after treatment. This is the number of people who are alive 3 years after diagnosis, and whose cancer has not grown or got worse. T3 tumours are larger than 5 cm and T4 tumours can be any size, but have grown into surrounding tissues or organs. These statistics are for relative survival. Relative survival takes into account that some people will die of causes other than cancer.
Immunotherapy Treatment Advances in Anal Cancer
Anal Cancer: Statistics | hannoufmediagroup.com
Skip to Content. You will also read general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see other pages. This year, an estimated 8, adults 2, men and 5, women in the United States will be diagnosed with anal cancer. White women and black men are more likely to be diagnosed with the disease. The average age of diagnosis for anal cancer is in the early 60s.
Prognostic Factors for Squamous Cell Cancer of the Anal Canal
Radiotherapy with concurrent chemotherapy is the standard of care for patients with nonmetastatic squamous cell anal cancer. Most patients treated with chemoradiotherapy have an excellent prognosis. However, some heterogeneity exists among anal cancer patients in their outcomes. This article reviews some of the clinical factors, treatment-related factors, and biologic factors that affect outcomes in patients with squamous cell anal cancer. The most important prognostic factors are the T and N stages.
Anal cancer is an abnormal growth of cells in or around the anus or anal canal, the short passage through which bowel movements pass. The most common type of cancer found in this location is believed to be related to a type of viral infection linked to causing other types of cancers as well. Anal cancers are usually treated with radiation and chemotherapy, but surgery alone may be useful for very small or early anal cancers or when other therapy is not an option or unsuccessful in treating the anal cancer. Assessment for cancer spread and close follow up are necessary when treating anal cancer.